Meet SPARDA, the Powerful New Alternative to CRISPR!

Introducing SPARDA: The Cutting-Edge Nucleic Acid Targeting Technology


What is SPARDA?

SPARDA stands for “short prokaryotic Argonaute, DNase, and RNase-associated.” It is a novel tool developed by researchers from the Russian Academy of Sciences. Unlike CRISPR, which utilizes Cas proteins, SPARDA is based on re-engineered prokaryotic Argonautes (pAgos). These pAgos have been modified to use RNA guides to locate specific nucleic acid sequences, effectively targeting DNA with high sensitivity.

How Does SPARDA Work?

The researchers have implemented a two-component system that harnesses the power of pAgos along with effector nucleases. This combination allows SPARDA to identify DNA sequences accurately and induce collateral nuclease activity. Such activity is crucial for the biotechnological applications of the system, as it can lead to the selective breakdown of targeted DNA strands within cells.

Key Features and Applications

One of the remarkable aspects of SPARDA is its activation mechanism, which can be triggered using plasmids or phages. This activation leads to the breakdown of cellular DNA, causing the death or dormancy of the targeted cells. This feature is particularly beneficial for providing targeted protection to specific cell populations and expanding the scope of recognized immune systems in prokaryotes.

Additionally, SPARDA’s ability to detect single-stranded DNA (ssDNA) targets with a fluorescent beacon assay sets it apart from other systems like Cas12 or Cas13. This method’s sensitivity can be further enhanced by incorporating a polymerase chain reaction (PCR) step before detection, making it a highly effective tool for in vitro nucleic acid detection.

The technology also boasts a physiological temperature range, low background activity, and the capacity to recognize specific motifs in target DNA. These characteristics make SPARDA suitable for a wide array of applications, including the programmable removal of bacterial or eukaryotic cells, which could revolutionize microbiome engineering and therapeutic interventions.

The Future of SPARDA

While the potential of SPARDA is immense, further research is needed to fully understand its capabilities and limitations. Studies are ongoing to determine whether SPARDA can permanently stop phage replication or simply delay the release of phages under various conditions.

As biotechnological tools like SPARDA continue to develop, they open new possibilities for genetic research and medical applications. SPARDA, with its unique mechanism and broad applicability, represents a significant step forward in the quest for precise, programmable nucleic acid targeting systems.


Li Y., Kumar N., Gopalakrishnan A., et al. Detection and species identification of malaria parasites by isothermal tHDA amplification directly from human blood without sample preparation. Journal of Molecular Diagnostics . 2013;15(5):634–641. doi: 10.1016/j.jmoldx.2013.05.005. – DOI – PMC – PubMed

Kersting S., Rausch V., Bier F. F., von Nickisch-Rosenegk M. Rapid detection of Plasmodium falciparum with isothermal recombinase polymerase amplification and lateral flow analysis. Malaria Journal . 2014;13(1):p. 99. doi: 10.1186/1475-2875-13-99. – DOI – PMC – PubMed

Schmidt B. A., Xu W., González I. J., et al. Loop mediated isothermal amplification (LAMP) accurately detects malaria DNA from filter paper blood samples of low density parasitaemias. PLoS One . 2014;9(8) doi: 10.1371/journal.pone.0103905.e103905 – DOI – PMC – PubMed

Deiman B., van Aarle P., Sillekens P. Characteristics and applications of nucleic acid sequence-based amplification (NASBA) Molecular Biotechnology . 2002;20(2):163–180. doi: 10.1385/MB:20:2:163. – DOI – PubMed

Hopkins H., González I. J., Polley S. D., et al. Highly sensitive detection of malaria parasitemia in a malaria-endemic setting: performance of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda. The Journal of Infectious Diseases . 2013;208(4):645–652. doi: 10.1093/infdis/jit184. – DOI – PMC – PubMed

Leave a Reply

Your email address will not be published. Required fields are marked *

Follow by Email
Post on X